This is clinical study to test, for the first time in people, the safety (anygood or bad effects), how long the drug can stay in the body and if it cancontrol the disease of people diagnosed with advanced cancer that has notresponded to treatment, has returned after it has been treated, or cannotbe treated by surgery, drugs, or any other known treatments.
Phase 1
- Conditions
- Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advancedbasal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternativedosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsedand/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104MedDRA version: 23.0Level: PTClassification code: 10029600Term: Non-Hodgkin's lymphoma recurrent Class: 100000004864MedDRA version: 23.0Level: PTClassification code: 10029601Term: Non-Hodgkin's lymphoma refractory Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10012822Term: Diffuse large B-cell lymphoma refractory Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10012821Term: Diffuse large B-cell lymphoma recurrent Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10004146Term: Basal cell carcinoma Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-509969-20-00
- Lead Sponsor
- Celgene Corp.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 133
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method